Detection of amyloid in intraportal islet implants of type 1 diabetes patients has been proposed as cause in their functional decline. The present study uses cultured adult human islets devoid of amyloid to examine conditions of its formation. After intraportal injection in patients, amyloid deposits <15µm diameter were identified in 5-12 percent of beta cell-containing aggregates, 3-76 months post-transplantation. Such deposits also formed in glucose-controlling islet implants in the kidney of diabetic mice but not in failing implants. Alginate-encapsulated islets formed amyloid during culture when functional, and in all intraperitoneal implants that corrected diabetes in mice, exhibiting larger sizes than in functioning non-encapsulated implants. After intraperitoneal injection in a patient, retrieved single capsules presented amyloid near living beta cells whereas no amyloid occurred in clustered capsules with dead cells. Amyloid was also demonstrated in functional human stem cell-generated beta cell implants in subcutaneous devices of mice. Deposits up to 35µm diameter were localized in beta cell-enriched regions and related to an elevated IAPP over insulin ratio in the newly generated beta cells. Amyloid in device-encapsulated human stem cell-generated beta cell implants marks formation of a functional beta cell mass but also an imbalance between its activated state and its microenvironment.

Original languageEnglish
JournalAmerican Journal of Transplantation
Publication statusE-pub ahead of print - 18 Nov 2020

Bibliographical note

© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.


  • type 1 diabetes
  • cultured adult human islets
  • Amyloid
  • Encapsulated Human Pancreatic cells
  • human
  • Human Stem Cell
  • Generated Beta Cell Implants

Fingerprint Dive into the research topics of 'Formation of amyloid in encapsulated human pancreatic and human stem cell-generated beta cell implants'. Together they form a unique fingerprint.

Cite this